Accordingly, either SOX2 depletion or inhibition of glycolysis by 2-DG led to a significant decrease in the tumor volume, tumor weight, uptake of 18F-FDG and SUVmax of xenografts, as well as VM formation in vivo (Figs. 1h–j, l and S1e). The gene discussed is SOX2; the disease is neoplasm.